AlzeCure's EIC Accelerator Backs an Alzheimer's Long Shot

The drugs that have reached the market in Alzheimer's either strip amyloid plaque from the brain or ease symptoms for a while. AlzeCure Pharma, based in Huddinge outside Stockholm, is pursuing a third mechanism: ACD856 is an oral first-in-class positive allosteric modulator of Trk receptors, designed to amplify signalling by BDNF and NGF, the neurotrophins that keep nerve cells functioning. In preclinical work the company reports stronger communication between nerve cells, better learning and memory, and neuroprotective, anti-inflammatory and disease-modifying effects.

The EIC Accelerator selected the project, NeuroRestore ACD856, at its October 2024 cut-off for blended finance, and CORDIS records a grant of €2,499,999 from August 2025 to July 2028, the longest project of this cut-off, for a phase II trial to demonstrate efficacy and to refine GMP manufacturing.

What phase Ib actually showed

On 16 June 2026 AlzeCure reported that its phase Ib study had completed on schedule. The result was safety, not efficacy: ACD856 was well tolerated with no substance-related safety findings, consistent with earlier human data, and concentrations rose as expected in both blood and cerebrospinal fluid after repeated dosing at higher levels than previously tested. The company says this broadens the therapeutic window and gives a basis for dose selection in future studies, and that it may widen the opportunity to include depression.

What the release does not give is the number of participants, the doses tested or the dose chosen, and independent coverage mostly repeats the company's framing. For a drug whose eventual claim is cognitive improvement and disease modification, this is the necessary groundwork rather than evidence that it works.

The trial the grant is for

The EIC money is specifically for the phase IIa study in Alzheimer's patients, which the company said in February 2025 the grant would support, along with testing higher doses in humans. Redeye's review of the first quarter of 2026 describes starting that study during 2026 as the company's key focus. As of October 2026 no start has been announced, and CORDIS shows no periodic report.

The project runs to July 2028, which is unusually long for this cut-off and realistic for a central nervous system trial. It also means the result that matters, whether ACD856 improves cognition in patients, will arrive at the very end of the grant or after it.

1. Safety and brain penetrationShownPhase I and phase Ib, the latter completed June 2026.
2. Dose selection for phase IICompany says yesPhase Ib described as providing a solid foundation for it.
3. Phase IIa in Alzheimer's patientsNot startedThe purpose of the grant; targeted for 2026.
4. Out-licensing dealNoneThe company's route to revenue, with milestones up to €250M projected.

Numbers worth reading twice

The project's commercial figures are extraordinary against the grant that supports them: milestone payments of up to €250 million from a licensing deal, market launch by 2033, and peak annual sales of €7 billion by 2037. They are the company's own projections and they describe an Alzheimer's drug that works, which is the single most valuable and least likely outcome in pharmaceutical development. For a listed company, projections like these are also an investor relations document as much as a grant application.

Why the EU funds a listed company's trial

Alzheimer's prevalence is projected to roughly double by 2050, and the project ties itself to the European Health Union's aim of reducing that burden. The reason a listed company needs non-dilutive money for a mid-stage trial is simple: small European biotechs cannot finance phase II from the market on preclinical promise, and the companies that can are American. The EIC grant is a bridge across that gap, with the licensing deal, not a product launch, as the realistic end point.